Immune-checkpoint inhibitors first became available for metastatic disease in 2017 and for patients with stage III disease in 2019, while BRAF inhibitors first became available for systemic disease in 2015 and for patients with stage III disease in 2020. The gene discussed is BRAF; the disease is metastatic neoplasm.